The key players are focusing on strategic mergers and acquisition and development of innovative products. For instance, Pfizer acquired Bamboo Therapeutics, a biotechnology company focused on developing gene therapies for the treatment of patients with diseases related to neuromuscular conditions and the diseases affecting central nervous system. The acquisition is expected to significantly expand Pfizer’s expertise in gene therapy by providing clinical and pre-clinical assets to balance the rare disease portfolio of company with advanced recombinant Adeno Associated Virus vector design and production technology, which is fully functional phase I/II gene therapy with manufacturing facilities. Furthermore key players operating in the market are focusing on transformation of medicines with artificial intelligence (AI). For instance in October 2019, Novartis is collaborated with Microsoft to transform medicine with artificial intelligence. With this collaboration the Novartis AI innovation lab and Microsoft as its strategic AI and data-science partner bolster Novartis AI capabilities. This would help Novartis to commercialization and help accelerate the discovery and development of transformative medicines for patients worldwide.
The key players operating the advanced therapy medicinal products market include Uniqure, Pfizer, Bluebird Bio Inc., BioMarin Pharmaceutical, Novartis AG, GE Healthcare, Shire Biotechnology, and Kite Pharma.
Advanced Therapy Medicinal Products Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients